XM does not provide services to residents of the United States of America.
S
S

Sage

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. CH Robinson Worldwide, Dayforce, Entegris

U.S. RESEARCH ROUNDUP-CH Robinson Worldwide, Dayforce, Entegris Aug 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CH Robinson Worldwide, Dayforce and Entegris, on Thursday. HIGHLIGHTS * CH Robinson Worldwide Inc CHRW.O : JP Morgan raises to overweight from neutral * Dayforce Inc DAY.N : Piper Sandler raises to overweight from neutral * Entegris Inc ENTG.O : Seaport Research Partners raises to buy from neutral * M
B
C
D
E
M
Q
S
V
A
C
D
E
L
T
P
W
A
B
C

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.70​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-2.68. The mean expectation of twenty analysts for the quarter was for a loss of $1.66 per share.
S

SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.66 a share - Earnings Preview

SAGE Therapeutics Inc expected to post a loss of $1.66 a share - Earnings Preview SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports results on July 31 for the period ending June 30 2024 The Cambridge Massachusetts-based company is expected to report a 258.2% increase in revenue to $8.848 million from $2.47 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
S

U.S. Edwards Lifesciences, National Bank Holdings, Sage Therapeutics

U.S. RESEARCH ROUNDUP-Edwards Lifesciences, National Bank Holdings, Sage Therapeutics July 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Edwards Lifesciences, National Bank Holdings and Sage Therapeutics, on Thursday. HIGHLIGHTS * Edwards Lifesciences Corp EW.N : JP Morgan cuts to neutral from overweight * National Bank Holdings Corp NBHC.N : Piper Sandler cuts to neutral from overweight * Sage Therapeutics Inc S
A
A
C
C
G
S
C
E
H
I
A
A
E
L

U.S. STOCKS Tesla, Lamb Weston, Blackstone Mortgage Trust

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings, prompting investors to question if the Big Tech and AI-fueled 2024 equity rally was sustainable in the long run.
A
C
F
G
M
S
S
T
V
C
T
U
U
E
T
L
O

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.